Can AI crack the R&D code?

Tuesday, October 14, 2025 | Georgia Room, NYC | Hybrid

AI has captured both Wall Street's attention and C-suites' imaginations. But beneath the headline-grabbing deals and billion-dollar valuations lies a fundamental question: Can AI actually deliver the biopharma breakthroughs it's promising?

Our most popular Endpoints Day returns this fall — bigger and bolder — with a full morning of virtual sessions and an exclusive, in-person evening of live-only editorial sessions and networking over food & drinks at NYC’s Georgia Room.

Just announced (in-person only): Hear from Pulitzer Prize-winning physician-author Siddhartha Mukherjee, whose new AI venture with Reid Hoffman aims to transform cancer research. He’ll share how his career in medicine, biotech, and writing shapes his vision for AI in drug discovery.

JOIN US

Choose your AI Day pass — in-person or virtual.

Led by award-winning senior biopharma correspondent Andrew Dunn, we're bringing together the industry's sharpest minds to tackle the hard questions. Is this AI's make-or-break moment for drug discovery? While some companies are already seeing real results in drug discovery and clinical trials, others are still figuring out how to move beyond the pilot phase. Is this the year AI proves its worth in biopharma?

What’s on the agenda?

Join us virtually in the morning for an editorial briefing, then in person that evening with exclusive, live editorial sessions and a networking reception in New York City.

Georgia Room, NYC

Only 25 seats left for in-person. Planning to be in NYC? Don’t wait to grab your spot.

AI isn't just having a moment in biopharma — it's having the moment. Companies that get AI right will define the next decade of drug development. Join us.

CHOOSE YOUR PASS